-
With the commencement of GMP manufacturing operations, OrganaBio’s CDMO offers the cell therapy industry ready access to flexible manufacturing solutions and clinical grade cellular raw materials.
-
OrganaBio, a cell therapy CDMO, expands manufacturing with ISO 7 cleanrooms for 3rd party manufacturing and GMP cellular starting material production.
Defined Bioscience to Develop Stem Cells and iPSC-derived Tissue for Life Science and Cultivated Meat Applications
Defined Bioscience Announces Formation of Its Scientific Advisory Board
San Diego, CA, June 15, 2022 —Â Defined Bioscience, a life science tools company pioneering the development of next generation ingredients for cell culture, today announced the formation of its scientific advisory board (SAB). The SAB is comprised of a distinguished group of academic and industry experts who will advise the Defined Bioscience team on the development and commercialization of cell culture reagents, growth medium and kits to consistently grow high quality stem cells and iPSC-derived tissue with applications in life science and cultivated meat. [Read more…]
Kimera Society Announces its 1st American Exosomes and RNA Conference
MIRAMAR, Fla., June 20, 2022 — Kimera® Society, a biotechnology non-profit research organization, is pleased to announce its first inaugural American Exosomes and RNA scientific, research and medical conference. [Read more…]
A new automated iPSC high-throughput induction system to induce thousands of iPSC lines simultaneously: To be presented at ISSCR 2022 Annual Meeting
Palo Alto, California, June 14, 2022 – I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based GMP cell manufacturing CDMO and personal iPSC banking provider, announced that the company has succeeded in developing a propriety automated iPSC high-throughput induction system to induce thousands of iPSC lines simultaneously. There are various automated cell processing/expansion systems in the market today, but this is the first high-throughput, automated cell processing system that is capable of inducing iPSCs from somatic cells. [Read more…]
Stem Cell Thought-Leaders—and What You Can Learn From Them
Without question, some of BioInformant’s most popular content has been our interviews with key opinion leaders (KOL). Highlighted below are five interviews that have been widely shared across the stem cell industry. The first interview with Dr. Sadiq has gotten more than 2,200 shares on social media, so you definitely need to check it out. Enjoy!
Stem Cell Therapy Shows Promise for Treatment of MS – Q&A with Dr. Sadiq of the Tisch MS Research Center of NY
In breaking news from the Tisch MS Research Center of New York, Dr. Sadiq announced he is pursuing a Phase II clinical trial exploring the use of stem cells in the treatment of MS. The announcement followed positive results from a FDA-approved Phase I stem cell trial in which MS patients received multiple spinal injections of neural progenitors derived from bone marrow mesenchymal stem cells (called MSC-NPs). Compellingly, it was the first time ever that a treatment method has demonstrated reversal of established disability in MS patients. [Read more…]
- « Previous Page
- 1
- …
- 144
- 145
- 146
- 147
- 148
- …
- 336
- Next Page »